{{Drugbox
| Watchedfields = changed
| verifiedrevid = 459980153
| IUPAC_name = (''RS'')-1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-<br/>3-(isopropylamino)propan-2-ol
| image = Bisoprolol.svg
| width = 240px
| chirality = [[Racemic mixture]]
<!--Clinical data-->
| tradename = Zebeta, Concor, others
| Drugs.com = {{drugs.com|monograph|bisoprolol-fumarate}}
| MedlinePlus = a693024
| licence_US = Bisoprolol
| pregnancy_AU = C
| pregnancy_US = C
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = by mouth
<!--Pharmacokinetic data-->
| bioavailability = >90%
| protein_bound = 30%<ref name="pmid2439794">{{cite journal |vauthors=Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A | title = Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans | journal = J. Cardiovasc. Pharmacol. | volume = 8 Suppl 11 | issue = | pages = S21–8 | year = 1986 | pmid = 2439794 | doi = 10.1097/00005344-198511001-00004| url = }}</ref>
| metabolism = 50% [[liver]], [[CYP2D6]], [[CYP3A4]]<ref>{{cite journal |url=http://onlinelibrary.wiley.com/doi/10.1021/js970316d/abstract |title=Pharmacokinetics and metabolism of bisoprolol enantiomers in humans |author1=Yuji Horikiri |author2=Takehiko Suzuki |author3=Masakazu Mizobe |journal=Journal of Pharmaceutical Sciences |volume=87 |issue=3 |pages=289–294 |date=March 1998 |doi=10.1021/js970316d |deadurl=no |archiveurl=https://web.archive.org/web/20141203225728/http://onlinelibrary.wiley.com/doi/10.1021/js970316d/abstract |archivedate=2014-12-03 |df= }}</ref>
| elimination_half-life = 10–12&nbsp;hours<ref name="pmid2439789">{{cite journal | author = Leopold G | title = Balanced pharmacokinetics and metabolism of bisoprolol | journal = J. Cardiovasc. Pharmacol. | volume = 8 Suppl 11 | issue = | pages = S16–20 | year = 1986 | pmid = 2439789 | doi = 10.1097/00005344-198511001-00003| url = }}</ref>
<!--Identifiers-->
| IUPHAR_ligand = 7129
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 66722-44-9
| ATC_prefix = C07
| ATC_suffix = AB07
| PubChem = 2405
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00612
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2312
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Y41JS2NL6U
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02342
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3127
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 645
<!--Chemical data-->
| C=18 | H=31 | N=1 | O=4
| molecular_weight = 325.443 g/mol
| smiles = O(c1ccc(cc1)COCCOC(C)C)CC(O)CNC(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VHYCDWMUTMEGQY-UHFFFAOYSA-N
}}
<!-- Definition and medical uses -->
'''Bisoprolol''', marketed under the tradename '''Zebeta''' among others, is a medication most commonly used for [[cardiovascular disease|heart disease]]s.<ref name=AHFS2016/> This specifically includes [[high blood pressure]], [[angina pectoris|chest pain from not enough blood flow to the heart]], and [[heart failure]].<ref name=AHFS2016/><ref>{{cite web|title=Bisoprolol 2.5mg/5mg/10mg film coated tablet - Summary of Product Characteristics (SPC) - (eMC)|url=https://www.medicines.org.uk/emc/medicine/25983|website=www.medicines.org.uk|accessdate=14 December 2016|date=18 February 2014|deadurl=no|archiveurl=https://web.archive.org/web/20161220180258/https://www.medicines.org.uk/emc/medicine/25983|archivedate=20 December 2016|df=}}</ref> It is taken by mouth.<ref name=AHFS2016/>

<!-- Side effects and mechanism -->
Common side effects include headache, feeling tired, diarrhea, and [[peripheral edema|swelling in the legs]].<ref name=AHFS2016/> More severe side effects include worsening [[asthma]], blocking the ability to recognize [[low blood sugar]], and worsening [[heart failure]].<ref name=Pro2016>{{cite web|title=Bisoprolol - FDA prescribing information, side effects and uses|url=https://www.drugs.com/pro/bisoprolol.html|website=www.drugs.com|accessdate=14 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221004233/https://www.drugs.com/pro/bisoprolol.html|archivedate=21 December 2016|df=}}</ref> There are concerns that use during [[pregnancy]] may be harmful to the baby.<ref>{{cite web|title=Bisoprolol (Zebeta) Use During Pregnancy|url=https://www.drugs.com/pregnancy/bisoprolol.html|website=www.drugs.com|accessdate=14 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221004229/https://www.drugs.com/pregnancy/bisoprolol.html|archivedate=21 December 2016|df=}}</ref> Bisoprolol is in the [[Beta blocker]] family of medications and is of the [[Beta blocker#.CE.B21-selective agents|β<sub>1</sub> selective]] type.<ref name=AHFS2016>{{cite web|title=Bisoprolol Fumarate|url=https://www.drugs.com/monograph/bisoprolol-fumarate.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161221004751/https://www.drugs.com/monograph/bisoprolol-fumarate.html|archivedate=21 December 2016|df=}}</ref> 

<!-- Society and culture -->
Bisoprolol was patented in 1976 and approved for medical use in 1986.<ref name=Fis2006>{{cite book|last1=Fischer|first1=Janos|last2=Ganellin|first2=C. Robin|title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=461|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA461|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170908140310/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA461|archivedate=2017-09-08|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> Bisoprolol is available as a [[generic medication]].<ref name=AHFS2016/> The wholesale cost in the [[developing world]] is about 2.98 to 4.94 USD per month.<ref name=ERC2014>{{cite web|title=Bisoprolol|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=BISO5T&s_year=2014&year=2014&str=5%20mg&desc=Bisoprolol&pack=new&frm=TAB-CAP&rte=PO&class_code2=12%2E4%2E&supplement=&class_name=%2812%2E1%2E%29Antianginal%20medicines%3Cbr%3E%2812%2E2%2E%29Antiarrhythmic%20medicines%3Cbr%3E%2812%2E3%2E%29Antihypertensive%20medicines%3Cbr%3E%2812%2E4%2E%29Medicines%20used%20in%20heart%20failure%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United States, as of 2015, it costs about 25 to 50 USD a month.<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=151}}</ref>

== Medical use ==
[[File:000859lg Zebeta 5 MG Oral Tablet.jpg|thumb|right|Zebeta 5-mg oral tablet]]
Bisoprolol is beneficial in treatment for  high blood pressure ([[hypertension]]), reduced blood flow to the heart (cardiac ischemia); [[congestive heart failure]], and preventive treatment before and primary treatment after heart attacks, decreasing the chances of recurrence.<ref name="r31">{{Cite journal | last1 = Rosenberg |first1 = J. | last2 = Gustafsson | first2 = F. | doi = 10.1517/14656566.9.2.293 | title = Bisoprolol for congestive heart failure | journal = Expert Opinion on Pharmacotherapy | volume = 9 | issue = 2 | pages = 293–300 | year = 2008 | pmid = 18201151 | pmc = }}</ref> Bisoprolol targets hypertension (elevated blood pressure).<ref name="r22">{{Cite journal | last1 = Amabile | first1 = G. | last2 = Serradimigni | first2 = A. | title = Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: Comparative double-blind trial | journal = European Heart Journal | volume = 8 Suppl M | pages = 65–69 | year = 1987 | pmid = 2967187 | doi=10.1093/eurheartj/8.suppl_m.65}}</ref><ref name="r32">{{Cite journal | last1 = Thadani | first1 = U. | title = Current medical management of chronic stable angina | journal = Journal of cardiovascular pharmacology and therapeutics | volume = 9 Suppl 1 | pages = S11–S29; quiz S29–9 | year = 2004 | pmid = 15378129 | doi=10.1177/107424840400900103}}</ref> In cardiac ischemia, the drug is used to reduce the activity of the heart muscle, so reduces oxygen and nutrient demand, and reduced blood supply can still transport sufficient amounts of oxygen and nutrients.<ref name=PMID7923660>{{Cite journal | title = A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees | journal = Circulation | volume = 90 | issue = 4 | pages = 1765–1773 | year = 1994 | pmid = 7923660| doi=10.1161/01.cir.90.4.1765}}</ref><ref name=PMID20354334>{{Cite journal | last1 = Konishi | first1 = M. | last2 = Haraguchi | first2 = G. | last3 = Kimura | first3 = S. | last4 = Inagaki | first4 = H. | last5 = Kawabata | first5 = M. | last6 = Hachiya | first6 = H. | last7 = Hirao | first7 = K. | last8 = Isobe | first8 = M. | title = Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure | journal = Circulation Journal | volume = 74 | issue = 6 | pages = 1127–1134 | year = 2010 | pmid = 20354334 | doi=10.1253/circj.cj-09-0989}}</ref><ref name=PMID20354032>{{Cite journal | last1 = Castagno | first1 = D. | last2 = Jhund | first2 = P. S. | last3 = McMurray | first3 = J. J. V. | last4 = Lewsey | first4 = J. D. | last5 = Erdmann | first5 = E. | last6 = Zannad | first6 = F. | last7 = Remme | first7 = W. J. | last8 = Lopez-Sendon | first8 = J. L. | last9 = Lechat | first9 = P. | doi = 10.1093/eurjhf/hfq038 | last10 = Follath | first10 = F. | last11 = Höglund | first11 = C. | last12 = Mareev | first12 = V. | last13 = Sadowski | first13 = Z. | last14 = Seabra-Gomes | first14 = R. J. | last15 = Dargie | first15 = H. J. | title = Improved survival with bisoprolol in patients with heart failure and renal impairment: An analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial | journal = European Journal of Heart Failure | volume = 12 | issue = 6 | pages = 607–616 | year = 2010 | pmid = 20354032 | pmc = }}</ref>

Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, [[arrhythmia]]s, [[ischemic heart disease]]s, and [[myocardial infarction]] after the acute event. Patients with compensated [[congestive heart failure]] may be treated with bisoprolol as a comedication (usually  with an [[ACE inhibitor]], a [[diuretic]], and a [[digitalis]]-glycosid, if indicated). In patients with congestive heart failure, it reduces the need for and the consumption of [[oxygen]] of the heart muscle. It is very important to start with low doses, as bisoprolol reduces also the muscular power of the heart, which is an undesired effect in congestive heart failure.{{mcn|date=November 2015}}

== Side effects ==
Overdose of bisoprolol leads to fatigue, hypotension,<ref name=PMID20354334/> low blood sugar,<ref name=PMID2878941/><ref name="pmid2876722"/> [[bronchospasm]]s, and [[bradycardia]].<ref name=PMID20354334/> Bronchospasms and low blood sugar because at high doses drug can be an antagonist for β<sub>2</sub> adrenergic receptors located in lung and in liver. Bronchospasm is due to blockage in lungs of β<sub>2</sub> receptor and low blood sugar because of decreased stimulation of glycogenolysis and gluconeogenesis in the liver via β<sub>2</sub> receptor.<ref name=PMID7923660/><ref name=PMID20354334/><ref name=PMID7858847>{{Cite journal | last1 = Hauck | first1 = R. W. | last2 = Schulz | first2 = C. | last3 = Emslander | first3 = H. P. | last4 = Böhm | first4 = M. | title = Pharmacological actions of the selective and non-selective beta-adrenoceptor antagonists celiprolol, bisoprolol and propranolol on human bronchi | journal = British Journal of Pharmacology | volume = 113 | issue = 3 | pages = 1043–1049 | year = 1994 | pmid = 7858847 | pmc = 1510470 | doi=10.1111/j.1476-5381.1994.tb17098.x}}</ref>

=== Cautions ===
Beta-blockers should generally be avoided in people with a history of asthma or bronchospasm as they may make the disease worse.<ref name=Pro2016/> A beta 1 selective beta blocker like bisoprolol may be tried in those in whom other options are not available.<ref name=Pro2016/>

== Mechanism of action ==

Bisoprolol is cardioprotective because it selectively and competitively blocks catecholamine (adrenalin) stimulation of β<sub>1</sub> adrenergic receptors (adrenoreceptors), which are mainly found in the heart muscle cells and heart conduction tissue (cardiospecific), but also found in juxtaglomerular cells in the kidney.<ref name=PMID7923660/> Normally, adrenalin and noradrenalin stimulation of the β<sub>1</sub> adrenoreceptor activates a signalling cascade (Gs protein and cAMP) which ultimately leads to increased contractility and increased heart rate of the heart muscle and heart pacemaker, respectively.<ref name=PMID2564629>{{Cite journal | last1 = Bristow | first1 = M. R. | last2 = Hershberger | first2 = R. E. | last3 = Port | first3 = J. D. | last4 = Minobe | first4 = W. | last5 = Rasmussen | first5 = R. | title = Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium | journal = Molecular Pharmacology | volume = 35 | issue = 3 | pages = 295–303 | year = 1989 | pmid = 2564629}}</ref> Bisoprolol competitively blocks the activation of this cascade, so decreases the adrenergic tone/stimulation of the heart muscle and pacemaker cells. Decreased adrenergic tone shows less contractility of heart muscle and  lowered heart rate of pacemakers.<ref name=PMID2878941>{{Cite journal | last1 = Leopold | first1 = G. | last2 = Pabst | first2 = J. | last3 = Ungethüm | first3 = W. | last4 = Bühring | first4 = K. U. | title = Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist | journal = Journal of clinical pharmacology | volume = 26 | issue = 8 | pages = 616–621 | year = 1986 | pmid = 2878941 | doi=10.1002/j.1552-4604.1986.tb02959.x}}</ref><ref name="pmid2876722">{{cite journal |vauthors=Leopold G, Ungethüm W, Pabst J, Simane Z, Bühring KU, Wiemann H |title=Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist |journal=Br J Clin Pharmacol |volume=22 |issue=3 |pages=293–300 |date=September 1986 |pmid=2876722 |pmc=1401121 |doi= 10.1111/j.1365-2125.1986.tb02890.x|url= }}</ref><ref name="pmid2439793"/>

== Pharmacology and biochemistry ==
[[Image:Bisoprolol selectivity.svg|400px|thumb|Selectivity of various β-blockers]]
Bisoprolol has both lipid- and water-soluble properties, making it a prime candidate over other β-blockers and even over other β<sub>1</sub>-blockers, being water-soluble, it has decreased incidence of central nervous system side effects (inability to diffuse into brain) compared to purely lipophilic compounds.<ref name=PMID2878941/><ref name="pmid2439793"/> Bisoprolol has an approximate half-life of 10–12 hours, and when ingested has nearly complete absorption into the blood stream.<ref name=PMID2878941/><ref name="pmid2876722"/> The high absorption is indicative of high bioavailability (approx. 90%).<ref name=PMID2878941/><ref name="pmid2876722"/> When being eliminated, the body evenly distributes it (50–50) between kidney excretion and liver biotransformation (then excreted).<ref name=PMID2878941/><ref name="pmid2876722"/><ref name="pmid2439793"/> These factors make it a convenient once/day dosage when administered.<ref name=PMID2878941/><ref name="pmid2876722"/>

=== β<sub>1</sub>-selectivity ===
Bisoprolol β<sub>1</sub>-selectivity is especially important in comparison to other nonselective beta blockers. The effects of the drug are limited to areas containing β<sub>1</sub> adrenoreceptors, which is mainly the heart and part of the kidney.<ref name=PMID2878941/><ref name="pmid2439793"/> Bisoprolol minimizes the side effects that might occur from administration of a nonspecific beta blocker where blockage of the other adrenoreceptors (β<sub>2</sub>, β<sub>3</sub>, α<sub>1</sub>, α<sub>2</sub>) occurs. The other receptors elicit a variety of responses in the body, and their blockage  could cause a wide range of reactions, but β<sub>1</sub> adrenoreceptors are cardiospecific for the most part, making bisoprolol ideal for treatment of cardiac events.<ref name=PMID2878941/><ref name="pmid2876722"/><ref name="pmid2439793"/>

Bisoprolol has a higher degree of β<sub>1</sub>-selectivity compared to other β<sub>1</sub>-selective β-blockers such as [[atenolol]], [[metoprolol]], and [[betaxolol]].<ref name="pmid2439793">{{cite journal |vauthors=Haeusler G, Schliep HJ, Schelling P |title=High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol |journal=J. Cardiovasc. Pharmacol. |volume=8 Suppl 11 |issue= |pages=S2–15 |year=1986 |pmid=2439793 |doi= 10.1097/00005344-198511001-00002|url=|display-authors=etal}}</ref><ref name="pmid2870720">{{cite journal |vauthors=Harting J, Becker KH, Bergmann R |title=Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol |journal=Arzneimittelforschung |volume=36 |issue=2 |pages=200–8 |date=February 1986 |pmid=2870720 |doi= |url=|display-authors=etal}}</ref><ref name="pmid2866449">{{cite journal |vauthors=Kaumann AJ, Lemoine H |title=Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(−)-bisoprolol with its blocking potency |journal=Naunyn Schmiedebergs Arch. Pharmacol. |volume=331 |issue=1 |pages=27–39 |date=October 1985 |pmid=2866449 |doi= 10.1007/bf00498849|url=}}</ref><ref name="pmid2870719">{{cite journal |vauthors=Klockow M, Greiner HE, Haase A, Schmitges CJ, Seyfried C |title=Studies on the receptor profile of bisoprolol |journal=Arzneimittelforschung |volume=36 |issue=2 |pages=197–200 |date=February 1986 |pmid=2870719 |doi= |url=}}</ref><ref name="pmid6113900">{{cite journal |vauthors=Manalan AS, Besch HR, Watanabe AM |title=Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung |journal=Circ. Res. |volume=49 |issue=2 |pages=326–36 |date=August 1981 |pmid=6113900 |doi= 10.1161/01.res.49.2.326|url=}}</ref><ref name="pmid3011461">{{cite journal |vauthors=Schliep HJ, Schulze E, Harting J, Haeusler G |title=Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats |journal=Eur. J. Pharmacol. |volume=123 |issue=2 |pages=253–61 |date=April 1986 |pmid=3011461 |doi= 10.1016/0014-2999(86)90666-7|url=}}</ref><ref name="pmid6084774">{{cite journal |vauthors=Schliep HJ, Harting J |title=Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs |journal=J. Cardiovasc. Pharmacol. |volume=6 |issue=6 |pages=1156–60 |year=1984 |pmid=6084774 |doi= 10.1097/00005344-198406060-00024|url=}}</ref><ref name="pmid11026647">{{cite journal |vauthors=Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Böhm M |title=Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors |journal=J. Cardiovasc. Pharmacol. |volume=36 |issue=4 |pages=466–71 |date=October 2000 |pmid=11026647 |doi= 10.1097/00005344-200010000-00008|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0160-2446&volume=36&issue=4&spage=466}}</ref><ref name="pmid10372227">{{cite journal |vauthors=Smith C, Teitler M |title=Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors |journal=Cardiovasc Drugs Ther |volume=13 |issue=2 |pages=123–6 |date=April 1999 |pmid=10372227 |doi= 10.1023/A:1007784109255|url=http://www.kluweronline.com/art.pdf?issn=0920-3206&volume=13&page=123}}</ref><ref name="pmid2439796">{{cite journal |vauthors=Wellstein A, Palm D, Belz GG |title=Affinity and selectivity of beta-adrenoceptor antagonists in vitro |journal=J. Cardiovasc. Pharmacol. |volume=8 Suppl 11 |issue= |pages=S36–40 |year=1986 |pmid=2439796 |doi= 10.1097/00005344-198511001-00006|url=}}</ref> However [[nebivolol]] is approximately 3.5 times more β<sub>1</sub>-selective.<ref name="pmid12535855">{{cite journal |vauthors=Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH |title=Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies |journal=Eur. J. Pharmacol. |volume=460 |issue=1 |pages=19–26 |date=January 2003 |pmid=12535855 |doi=10.1016/S0014-2999(02)02875-3 |url=}}</ref><ref name="pmid12795776">{{cite journal |vauthors=Nuttall SL, Routledge HC, Kendall MJ |title=A comparison of the beta1-selectivity of three beta1-selective beta-blockers |journal=J Clin Pharm Ther |volume=28 |issue=3 |pages=179–86 |date=June 2003 |pmid=12795776 |doi= 10.1046/j.1365-2710.2003.00477.x|url=}}</ref>

=== Renin-angiotensin system ===
Bisoprolol inhibits renin secretion by about 65% and tachycardia by about 30%.<ref name="pmid2870720"/>

==Society and culture==
Bisoprolol is available as a generic medication and has been approved by the FDA for manufacture by Teva, Mylan, Sandoz, Aurobino, and Unichem.<ref>{{Cite web| title = Drugs@FDA: FDA Approved Drug Products| accessdate = 2013-11-13| url = http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BISOPROLOL%20FUMARATE| deadurl = no| archiveurl = https://web.archive.org/web/20150225122551/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BISOPROLOL%20FUMARATE| archivedate = 2015-02-25| df = }}</ref>

==History==
Bisoprolol was patented in 1976 and approved for medical use in 1986.<ref name=Fis2006/> It was approved for medical use in the United States in 1992.<ref name=AHFS2016/>

==References==
{{reflist|32em}}

==External links==

{{beta blockers}}

[[Category:Beta blockers]]
[[Category:Ethers]]
[[Category:Phenol ethers]]
[[Category:Alcohols]]
[[Category:Peripherally selective drugs]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]